Literature DB >> 11469822

Management of systemic vasculitis.

C A Langford1.   

Abstract

The systemic vasculitides are a wide-ranging group of diseases that are characterized by the presence of blood vessel inflammation. Despite this common feature, each type of vasculitis has a unique variety of clinical manifestations that influences its degree of disease severity and ultimately its management. Immunosuppressive therapy forms the foundation of treatment for almost all forms of systemic vasculitis. Because of this, treatment can be associated with its own risk of morbidity, or even mortality, related to specific medication side-effects or infections which occur as a result of impaired host defences. This chapter seeks to review the approach to management in selected forms of systemic vasculitis. Questions examined include the following. When should one treat systemic vasculitis? How does the nature of the disease and its severity affect treatment decisions? What are the data regarding the effectiveness of individual therapeutic regimens? Copyright 2001 Harcourt Publishers Ltd.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11469822     DOI: 10.1053/berh.2001.0144

Source DB:  PubMed          Journal:  Best Pract Res Clin Rheumatol        ISSN: 1521-6942            Impact factor:   4.098


  4 in total

1.  Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology.

Authors:  F Buttgereit; J A P da Silva; M Boers; G-R Burmester; M Cutolo; J Jacobs; J Kirwan; L Köhler; P Van Riel; T Vischer; J W J Bijlsma
Journal:  Ann Rheum Dis       Date:  2002-08       Impact factor: 19.103

2.  Extra corporeal membrane oxygenation and plasmapheresis for pulmonary hemorrhage in microscopic polyangiitis.

Authors:  Hemant Shyam Agarwal; Mary Barraza Taylor; Marek Janusz Grzeszczak; Harold Newt Lovvorn; Tracy Earl Hunley; Kathy Jabs; Venkatramanan Shankar
Journal:  Pediatr Nephrol       Date:  2005-02-16       Impact factor: 3.714

3.  Role of ursodeoxycholic acid in prevention of methotrexate-induced liver toxicity.

Authors:  Suleyman Uraz; Veysel Tahan; Cem Aygun; Fatih Eren; Goksenin Unluguzel; Meral Yuksel; Omer Senturk; Erol Avsar; Goncagul Haklar; Cigdem Celikel; Sadettin Hulagu; Nurdan Tozun
Journal:  Dig Dis Sci       Date:  2007-10-13       Impact factor: 3.199

4.  Microscopic polyangiitis complicated by the development of prostate cancer and flutamide-induced hepatitis.

Authors:  D Papaioannides; P Korantzopoulos; C Bouropoulos; P Latsi; M Fotinou; D Orphanidou
Journal:  Int Urol Nephrol       Date:  2005       Impact factor: 2.266

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.